Fortress Biotech, Inc. Notes Payable, Noncurrent
Fortress Biotech, Inc. (FBIO) had Notes Payable, Noncurrent of $34.60 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:LongTermNotesPayable · last filed 2026-08-13
- 2026-06-30: Notes Payable, Noncurrent $34.60M.
- 2026-03-31: Notes Payable, Noncurrent $36.88M.
- 2025-12-31: Notes Payable, Noncurrent $52.42M.
- 2025-09-30: Notes Payable, Noncurrent $47.77M.
| Period end | Notes Payable, Noncurrent | Notes Payable, Noncurrent as first filed |
|---|---|---|
| 2026-06-30 | $34.60M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $36.88M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $52.42M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $47.77M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $50.03M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $56.38M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $57.96M 10-K · filed 2026-03-31 | |
| 2024-09-30 | $52.47M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $67.01M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $61.42M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $60.86M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $45.79M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $45.33M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $90.00M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $91.73M 10-K · filed 2024-03-28 | |
| 2022-09-30 | $91.17M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $85.61M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $85.06M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $42.94M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $42.57M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $52.26M 10-Q · filed 2021-08-16 | |
| 2021-03-31 | $51.99M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $51.68M 10-K · filed 2022-03-28 | |
| 2020-09-30 | $51.39M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $64.16M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $70.87M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $77.44M 10-K/A · filed 2021-04-09 | |
| 2019-09-30 | $68.54M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $74.31M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $73.61M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $60.42M 10-K · filed 2020-03-16 | |
| 2018-09-30 | $64.55M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $73.46M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $73.44M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $39.21M 10-K · filed 2019-03-18 | $43.22M 10-K · filed 2018-03-16 |
| 2017-09-30 | $40.73M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $39.27M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $26.14M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $22.53M 10-K · filed 2018-03-16 | |
| 2016-09-30 | $24.37M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $20.80M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $20.75M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $23.17M 10-K · filed 2017-03-16 | |
| 2015-09-30 | $23.29M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $23.23M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $24.01M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $14.00M 10-K · filed 2016-03-15 | $14.01M 10-K · filed 2015-03-16 |
| 2014-09-30 | $14.01M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $14.01M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $14.01M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $7.02M 10-K · filed 2015-03-16 | |
| 2013-09-30 | $8.41M 10-Q · filed 2013-11-01 | |
| 2013-06-30 | $9.76M 10-Q · filed 2013-08-05 | |
| 2013-03-31 | $11.09M 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $12.39M 10-K · filed 2014-03-14 | |
| 2012-09-30 | $14.09M 10-Q · filed 2012-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |